Reviewing ZIOPHARM Oncology Inc. (ZIOP)’s and ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)’s results

As Biotechnology companies, ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ZIOPHARM Oncology Inc. N/A 3996.02 137.25M -0.54 0.00
ASLAN Pharmaceuticals Limited N/A 0.00 N/A -0.32 0.00

In table 1 we can see ZIOPHARM Oncology Inc. and ASLAN Pharmaceuticals Limited’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of ZIOPHARM Oncology Inc. and ASLAN Pharmaceuticals Limited.

Net Margins Return on Equity Return on Assets
ZIOPHARM Oncology Inc. 0.00% 58.6% -89.9%
ASLAN Pharmaceuticals Limited 0.00% 0% 0%

Analyst Recommendations

The following table given below contains the ratings and recommendations for ZIOPHARM Oncology Inc. and ASLAN Pharmaceuticals Limited.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ZIOPHARM Oncology Inc. 0 0 2 3.00
ASLAN Pharmaceuticals Limited 0 0 0 0.00

ZIOPHARM Oncology Inc.’s average price target is $5.25, while its potential upside is 45.43%.

Institutional and Insider Ownership

ZIOPHARM Oncology Inc. and ASLAN Pharmaceuticals Limited has shares owned by institutional investors as follows: 39.8% and 9.35%. Insiders owned 1.7% of ZIOPHARM Oncology Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ZIOPHARM Oncology Inc. -12.58% 20.98% -25.14% -3.9% -25.14% 44.92%
ASLAN Pharmaceuticals Limited 12.66% 4.4% -34.07% -54.53% 0% -1.11%

For the past year ZIOPHARM Oncology Inc. had bullish trend while ASLAN Pharmaceuticals Limited had bearish trend.

Summary

On 6 of the 8 factors ZIOPHARM Oncology Inc. beats ASLAN Pharmaceuticals Limited.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais (RON) inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors. It is also developing ASLAN004, a monoclonal IL4/IL13 antibody that is under preclinical development for asthma and other tumor types; and ASLAN005, a monoclonal antibody, which is under preclinical development for RON, an immune checkpoint inhibitor. In addition, the company is also discovering Modybodies that are a novel type of antibody fragments, which can be linked together into heterodimers/trimers to inhibit various targets. ASLAN Pharmaceuticals Limited was founded in 2014 and is headquartered in Singapore.